{
    "K143467.txt": {
        "510k number": "k143467",
        "applicant": "TaiDoc Technology Corporation",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The FORA GD43 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood from the fingertip and alternative sites (palm, forearm and upper arm).",
        "intended use": "The FORA GD43 Blood Glucose Monitoring System is intended to be used by a single person and should not be shared. Alternative site testing (AST) should only be done during steady-state times (when glucose is not changing rapidly).",
        "measurand": "Capillary whole blood glucose from the fingertip, palm, forearm, and upper arm",
        "panel": "Clinical Chemistry (75)",
        "predicate 510k number": "k101509",
        "predicate device name": "FORA GD40 Blood Glucose Monitoring System",
        "product code": "NBW, System, Test, Blood Glucose, Over the Counter, LFR, Glucose Dehydrogenase, Glucose",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "FORA GD43 Blood Glucose Monitoring System",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 862.1345, Glucose test system",
        "type of test": "Quantitative amperometric assay, glucose dehydrogenase (GDH-FAD)"
    },
    "K171742.txt": {
        "510k number": "K171742",
        "applicant": "Siemens Healthcare Diagnostics Products GmbH",
        "classification": "Class II, test systems",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "In-vitro diagnostic reagents for the quantitative determination of free light chains (FLC), type kappa or type lambda in human serum and EDTA-plasma by means of particle-enhanced immunonephelometry using the BN Systems.",
        "intended use": "In-vitro diagnostic reagents for the quantitative determination of free light chains (FLC), type kappa or type lambda in human serum and EDTA-plasma by means of particle-enhanced immunonephelometry using the BN Systems.",
        "measurand": "Kappa (\u03ba) Free Light Chain (FLC), Lambda (\u03bb) Free Light Chain (FLC)",
        "panel": "Immunology (82)",
        "predicate 510k number": "K031016",
        "predicate device name": "The Binding Site Freelite Human Kappa Free Kit, The Binding Site Freelite Human Lambda Free Kit",
        "product code": "DFH, Kappa, antigen, antiserum, control, DEH, Lambda, antigen, antiserum, control",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.",
        "proprietary and established names": "N Latex FLC Kappa assay, N Latex FLC Lambda assay, N FLC Standard SL, N FLC Control SL1 & SL2",
        "purpose for submission": "New device on two previously cleared instruments",
        "regulation section": "21 CFR \u00a7 866.5550 \u2013 Immunoglobulin (light chain specific) immunological test system, 21 CFR \u00a7 862.1660 \u2013 Quality Control Material (assayed and unassayed)",
        "type of test": "Nephelometry, quantitative"
    },
    "K170491.txt": {
        "510k number": "K170491",
        "applicant": "Quidel Corporation",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "Same as Intended Use",
        "intended use": "The Solana C. difficile assay is an in vitro diagnostic test for the direct, qualitative detection of the Clostridium difficile Toxin A gene (tcdA) in unformed stool specimens of patients suspected of having Clostridium difficile infection (CDI)",
        "measurand": "tcdA gene of toxigenic Clostridium difficile",
        "panel": "Microbiology (83)",
        "predicate 510k number": "K113358 (DEN120013)",
        "predicate device name": "Portrait Toxigenic C. difficile Assay",
        "product code": "OZN",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "Solana C. difficile Assay",
        "purpose for submission": "To obtain a substantial equivalence determination for a new device",
        "regulation section": "21 CFR 866.3130, Clostridium difficile toxin gene amplification assay",
        "type of test": "Qualitative Helicase-Dependent Amplification (HDA) assay"
    },
    "K161220.txt": {
        "510k number": "K161220",
        "applicant": "Luminex Corporation",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as intended use",
        "intended use": "The ARIES Flu A/B & RSV Assay is a polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) nucleic acid in nasopharyngeal swab (NPS) specimens from patients with signs and symptoms of respiratory tract infection in conjunction with clinical and laboratory findings.",
        "measurand": "Influenza A RNA: Matrix gene, Influenza B RNA: Matrix gene, Respiratory Syncytial Virus (RSV) RNA: Fusion gene of RSV A and RSV B",
        "panel": "Microbiology (83)",
        "predicate 510k number": "K120413",
        "predicate device name": "Simplexa Flu A/B & RSV Direct",
        "product code": "OCC, OOI, OZE",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "ARIES Flu A/B & RSV Assay",
        "purpose for submission": "Clearance of New Device",
        "regulation section": "21 CFR 866.3980",
        "type of test": "Qualitative Real Time Polymerase Chain Reaction (PCR)"
    },
    "K172913.txt": {
        "510k number": "K172913",
        "applicant": "Roche Molecular Systems, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Aid in the diagnosis of patients with suspected thrombophilia",
        "intended use": "The cobas Factor II and Factor V Test is an in vitro diagnostic device that uses real-time PCR for the detection and genotyping of the Factor II (Prothrombin) G20210A mutation and the Factor V Leiden G1691A mutation in genomic DNA obtained from K2EDTA whole blood specimens as an aid in diagnosis of patients with suspected thrombophilia.",
        "measurand": "Factor II and Factor V",
        "panel": "Hematology (81)",
        "predicate 510k number": "K033612, K033607",
        "predicate device name": "Roche Factor II (Prothrombin) G20210A Kit, Roche Factor V Leiden Kit",
        "product code": "NPR; Test, Factor II G20210A Mutations, Genomic DNA PCR, Factor V Leiden DNA Mutation Detection Systems, NPQ; Test, Factor V Leiden Mutations, Genomics DNA PCR, Factor V Leiden DNA Mutation Detection Systems",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.",
        "proprietary and established names": "cobas Factor II and Factor V Test",
        "purpose for submission": "To obtain clearance for a new device",
        "regulation section": "21 CFR 84.7280; Factor V Leiden DNA Mutation Detection Systems",
        "type of test": "Genotyping test"
    },
    "K160082.txt": {
        "510k number": "K160082",
        "applicant": "Puritan Medical Products, LLC",
        "classification": "Class I",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "Same as intended use",
        "intended use": "The Puritan Opti-Tranz Cary-Blair Collection and Transport System is intended for use in the collection and transport of clinical fecal and rectal swab specimens to preserve the viability of enteric bacteria during transport from the collection site to the testing laboratory for bacteriological examination and culture",
        "measurand": "Not applicable",
        "panel": "83- Microbiology",
        "predicate 510k number": "k946286",
        "predicate device name": "Copan Venturi Transystem Cary-Blair Medium product (132C)",
        "product code": "JSM; Culture Media, Non-Propagating Transport",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "Puritan Opti-Tranz Cary-Blair Collection and Transport System",
        "purpose for submission": "To make a substantial equivalence determination for the Puritan Opti-Tranz Cary-Blair Collection and Transport System for the collection, transport and storage of fecal specimens for laboratory culture of bacteria and yeast",
        "regulation section": "866.2390; Transport Culture Medium",
        "type of test": "Collection and transport culture medium device"
    },
    "K180886.txt": {
        "510k number": "K180886",
        "applicant": "Liofilchem s.r.l.",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "measurand": "Delafloxacin 0.002-32 \u03bcg/mL",
        "panel": "83 \u2013 Microbiology",
        "predicate 510k number": "K153687",
        "predicate device name": "Liofilchem MTS, vancomycin",
        "product code": "JWY - Manual Antimicrobial Susceptibility Test Systems",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Liofilchem MIC Test Strip (MTS), Delafloxacin 0.002-32 \u03bcg/mL",
        "purpose for submission": "To obtain a substantial equivalence for the addition of Delafloxacin at concentrations of 0.002-32 \u00b5g/mL for susceptibility testing of non-fastidious Gram negative organisms",
        "regulation section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "type of test": "Quantitative Antimicrobial Susceptibility Test growth based detection"
    },
    "K153278.txt": {
        "510k number": "k153278",
        "applicant": "Andon Health Co., Ltd",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "The iHealth Wireless Gluco-Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip, palm, forearm, upper arm, calf, or thigh",
        "intended use": "The iHealth Wireless Gluco-Monitoring System is intended to be used by a single person and should not be shared",
        "measurand": "Capillary Whole Blood Glucose from the fingertip palm, forearm, upper arm, calf or thigh",
        "panel": "(75) Chemistry",
        "predicate 510k number": "k123935",
        "predicate device name": "iHealth BG5 Wireless Smart Gluco-Monitoring System",
        "product code": "NBW",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "iHealth Wireless Smart Gluco-Monitoring System (BG5)",
        "purpose for submission": "Modified devices to add compatibility with Android mobile platforms",
        "regulation section": "21 \u00a7 862.1345",
        "type of test": "Quantitative, amperometric assay, glucose oxidase"
    },
    "K181525.txt": {
        "510k number": "K181525",
        "applicant": "Siemens Healthcare Diagnostics Product GmbH",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "For the quantitative determination of free protein S antigen in human plasma collected from venous blood samples in 3.2% sodium citrate tubes on the Sysmex CS-5100 analyzer. As an aid in the diagnosis of protein S deficiency in patients who are suspected of free protein S deficiency.",
        "measurand": "Free Protein S Antigen (%)",
        "panel": "Hematology (81)",
        "predicate 510k number": "K010963",
        "predicate device name": "STA-Liatest Free Protein S",
        "product code": "GGP",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 809.10.",
        "proprietary and established names": "INNOVANCE Free PS Ag",
        "purpose for submission": "New Device",
        "regulation section": "21 CFR 864.7290",
        "type of test": "Quantitative immunoturbidimetric assay"
    },
    "K190223.txt": {
        "510k number": "K190223",
        "applicant": "Microbiologics, Inc.",
        "classification": "Class II (Special Controls)",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "Same as Intended Use",
        "intended use": "The Cepheid Xpert CT/NG Control Panel is intended for use as an external assayed positive and negative quality control to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) performed with the Cepheid Xpert CT/NG assay on the GeneXpert Instrument System.",
        "measurand": "Nucleic acids from inactivated Chlamydia trachomatis and Neisseria gonorrhoeae (positive control) and from human epithelial cells (negative control)",
        "panel": "(83) Microbiology",
        "predicate 510k number": "K182472",
        "predicate device name": "Cepheid Xpert GBS LB Control Panel",
        "product code": "2",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device",
        "proprietary and established names": "Trade Name: Cepheid Xpert CT/NG Control Panel",
        "purpose for submission": "To obtain a substantial equivalence determination for the Cepheid Xpert CT/NG Control Panel for use with the Cepheid Xpert CT/NG Assay on the GeneXpert Instrument System",
        "regulation section": "21 CFR 866.3920, Assayed quality control material for clinical microbiology assays",
        "type of test": "The Cepheid Xpert CT/NG Control Panel is an external assayed quality control material (positive and negative) designed to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Chlamydia trachomatis and Neisseria gonorrhoeae in genitourinary specimens when used with the Cepheid Xpert CT/NG assay on the Cepheid Xpert Instrument System"
    },
    "K162042.txt": {
        "510k number": "k162042",
        "applicant": "OptiScan Biomedical Corporation",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The OptiScanner 5000 Glucose Monitoring System is an automated, bedside glucose monitoring device indicated for detecting trends and tracking patterns in persons (age 18 and older) in the surgical intensive care unit.",
        "intended use": "The OptiScanner 5000 Glucose Monitoring System is intended for hospital bedside glucose monitoring for detecting trends and tracking patterns in glucose",
        "measurand": "Plasma glucose from central venous catheter blood draw",
        "panel": "Clinical Chemistry",
        "predicate 510k number": "k951739",
        "predicate device name": "VIA Medical Corp Pump/Blood Chemistry Monitor",
        "product code": "LZF",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "OptiScanner 5000 Glucose Monitoring System",
        "purpose for submission": "New device",
        "regulation section": "21 CFR \u00a7880.5725",
        "type of test": "Quantitative, mid-infrared (MIR) spectrophotometric assay"
    },
    "K171770.txt": {
        "510k number": "K171770",
        "applicant": "Roche Molecular Systems, Inc.",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The cobas Cdiff Nucleic acid test for use on the cobas Liat System is an automated, qualitative in vitro diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the detection of the toxin B (tcdB) gene of toxigenic Clostridium difficile in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI).",
        "measurand": "tcdB gene of toxigenic Clostridium difficile",
        "panel": "Microbiology (83)",
        "predicate 510k number": "K142422",
        "predicate device name": "cobas Cdiff Test for use on the cobas 4800 System",
        "product code": "OZN, OOI",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "cobas Cdiff Nucleic acid test for use on the cobas Liat System",
        "purpose for submission": "To obtain a substantial equivalence determination for the cobas Cdiff Nucleic acid test for use on the cobas Liat System",
        "regulation section": "21 CFR 866.3130, Clostridium difficile toxin gene amplification assay",
        "type of test": "Real-time PCR assay"
    },
    "K171641.txt": {
        "510k number": "K171641",
        "applicant": "Mesa Biotech, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The Accula Flu A/Flu B Test performed on the Accula Dock is a molecular in vitro diagnostic test utilizing polymerase chain reaction (PCR) and lateral flow technologies for the qualitative, visual detection and differentiation of influenza A and influenza B viral RNA.",
        "measurand": "Influenza A PB2 RNA, Influenza B Matrix RNA",
        "panel": "Microbiology (83)",
        "predicate 510k number": "K141520",
        "predicate device name": "Alere i Influenza A&B",
        "product code": "OZE - Influenza A and Influenza B Multiplex Nucleic Acid Assay",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.",
        "proprietary and established names": "Accula Flu A/Flu B Test",
        "purpose for submission": "This is a new 510(k) application for the determination of Substantial Equivalence for the Mesa Biotech Accula Flu A/Flu B Test and associated instrument.",
        "regulation section": "21 CRF 866.3980, Respiratory viral panel multiplex nucleic acid assay",
        "type of test": "RT-PCR amplification followed by hybridization and colorimetric visualization of amplified products on a test strip"
    },
    "K180559.txt": {
        "510k number": "K180559",
        "applicant": "ELITechGroup Inc. Molecular Diagnostics",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as intended use",
        "intended use": "The HSV 1&2 ELITe MGB Assay is a real-time polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and differentiation of Herpes Simplex Virus 1 and 2 (HSV-1 and HSV-2) DNA in cutaneous or mucocutaneous lesion swab specimens from patients with signs and symptoms of HSV-1 or HSV-2 infection.",
        "measurand": "Target DNA Sequences from conserved regions of Herpes Simplex Virus Type 1 (HSV-1) and Herpes Simplex Virus Type 2 (HSV-2)",
        "panel": "83 - Microbiology",
        "predicate 510k number": "K151906",
        "predicate device name": "ARIES HSV 1&2 Assay",
        "product code": "PGI",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.",
        "proprietary and established names": "HSV 1&2 ELITe MGB Assay",
        "purpose for submission": "Clearance of New Device",
        "regulation section": "21CFR 866.3309",
        "type of test": "Qualitative Real-Time PCR Assay"
    },
    "K160538.txt": null,
    "K151923.txt": {
        "510k number": "K151923",
        "applicant": "bioM\u00e9rieux, Inc.",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "VITEK 2 Yeast Micafungin is designed for antifungal susceptibility testing of Candida species.",
        "intended use": "The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.",
        "measurand": "The VITEK 2 AST Yeast card contains the following concentration of Micafungin: 0.06, 0.25, 1 and 4\u03bcg/mL.",
        "panel": "83 Microbiology",
        "predicate 510k number": "K133952",
        "predicate device name": "VITEK 2 AST-YS Flucytosine",
        "product code": "NGZ \u2013 Susceptibility Test Plate, Antifungal",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "VITEK 2 AST-Yeast Micafungin (0.06 - 8 \u00b5g/mL)",
        "purpose for submission": "To obtain a substantial equivalence determination for the addition of Micafungin to the VITEK 2 and VITEK 2 Compact Systems Antimicrobial Susceptibility Test (AST) Systems",
        "regulation section": "21 CFR 866.1640, Antimicrobial Susceptibility Test Powder",
        "type of test": "Automated quantitative or qualitative antifungal susceptibility test of Candida species to Micafungin"
    },
    "K182472.txt": {
        "510k number": "K182472",
        "applicant": "Microbiologics, Inc.",
        "classification": "Class II (Special Controls)",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The Cepheid Xpert GBS LB Control Panel is intended for use as external assayed positive and negative quality control materials to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Group B Streptococcus (GBS) performed with the Cepheid Xpert GBS LB Assay on the GeneXpert Instrument System.",
        "measurand": "Nucleic acid quality control material from inactivated Streptococcus agalactiae and Lactobacillus acidophilus bacterial cultures for detection of Streptococcus agalactiae (Group B Streptococcus positive control) and Lactobacillus acidophilus (negative control).",
        "panel": "83 - Microbiology",
        "predicate 510k number": "DEN150058",
        "predicate device name": "Bio-Rad Amplichek II",
        "product code": "PMN: Assayed external control material for microbiology nucleic acid amplification assays",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device.",
        "proprietary and established names": "Cepheid Xpert GBS LB Control Panel",
        "purpose for submission": "To obtain a Substantial Equivalence determination for the Cepheid Xpert GBS LB Control Panel for use with the Cepheid Xpert GBS LB Assay on the GeneXpert Instrument System.",
        "regulation section": "21 CFR 866.3920: Assayed quality control material for clinical microbiology assays",
        "type of test": "The Cepheid Xpert GBS LB Control Panel is an external assayed positive and negative quality control materials to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Streptococcus agalactiae (GBS) performed with the Cepheid Xpert GBS LB Assay on the GeneXpert Instrument System."
    },
    "K162688.txt": {
        "510k number": "K162688",
        "applicant": "Siemens Healthcare Diagnostics Product GmbH",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use(s) above",
        "intended use": "The Sysmex CS-2100i is a fully automated blood coagulation analyzer intended for in vitro diagnostic use using plasma collected from venous blood samples in 3.2% sodium citrate tubes to analyze clotting, chromogenic and immunoassay methods in the clinical laboratory.",
        "measurand": "Factor V activity using Coagulation Factor V Deficient Plasma; factor VII activity using Coagulation Factor VII Deficient Plasma; protein C activity using Protein C Reagent and protein C activity using Berichrom Protein C.",
        "panel": "Hematology (81)",
        "predicate 510k number": "K011235",
        "predicate device name": "Sysmex Automated Coagulation Analyzer CA-1500",
        "product code": "JPA, System, multipurpose for in vitro coagulation studies",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Sysmex CS-2100i Automated Blood Coagulation Analyzer, Coagulation Factor V Deficient Plasma, Coagulation Factor II, VII and X Deficient Plasmas, Protein C Reagent, Berichrom Protein C",
        "purpose for submission": "To expand the use of previously cleared assay reagents for Coagulation Factor V Deficient Plasma, Coagulation Factor VII Deficient Plasma, Protein C Reagent, and Berichrom Protein C to the Sysmex CS-2100i automated blood coagulation analyzer.",
        "regulation section": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies",
        "type of test": "Quantitative clot-based applications and quantitative chromogenic application"
    },
    "K190332.txt": {
        "510k number": "K190332",
        "applicant": "Leica Biosystems Imaging, Inc.",
        "classification": "Class II (special controls)",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use.",
        "intended use": "The Aperio AT2 DX System is an automated digital slide creation and viewing system. The Aperio AT2 DX System is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue.",
        "measurand": "Not applicable",
        "panel": "88 - Pathology",
        "predicate 510k number": "DEN160056",
        "predicate device name": "Philips IntelliSite Pathology Solution (PIPS)",
        "product code": "PSY",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable, and the special controls for this device type under 21 CFR 864.3700.",
        "proprietary and established names": "Aperio AT2 DX System",
        "purpose for submission": "New Whole Slide Imaging (WSI) system",
        "regulation section": "21 CFR 864.3700",
        "type of test": "Digital pathology whole slide imaging"
    },
    "K151046.txt": null,
    "K172333.txt": {
        "510k number": "K172333",
        "applicant": "Siemens Healthcare Diagnostics Product GmbH",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use(s) above",
        "intended use": "The Sysmex Automated Blood Coagulation Analyzer CS-5100 is a fully automated blood coagulation analyzer intended for in vitro diagnostic use using plasma collected from venous blood samples in 3.2% sodium citrate tubes to analyze clotting, chromogenic and immunoassay methods in the clinical laboratory.",
        "measurand": "Factor V Leiden activity with Factor V Leiden Assay; Factor VIII activity with Dade Actin FSL Activated PTT Reagent; Factor IX activity with Dade Actin FSL Activated PTT Reagent; Lupus Anticoagulant with LA 1 Screening Reagent; Lupus Anticoagulant with LA 2 Confirmation Reagent and Lupus Anticoagulant with LA Ratio.",
        "panel": "Hematology (81)",
        "predicate 510k number": "K011235",
        "predicate device name": "Sysmex CA-1500",
        "product code": "JPA, System, multipurpose for in vitro coagulation studies",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Sysmex Automated Blood Coagulation Analyzer CS-5100",
        "purpose for submission": "To expand the use of previously cleared assay reagents for Factor V Leiden; Coagulation Factor VIII Deficient Plasma; Coagulation Factor IX Deficient Plasma; Lupus Anticoagulant with LA 1 Screening Reagent; Lupus Anticoagulant with LA 2 Confirmation Reagent and Lupus Anticoagulant with LA 1 / LA 2 Ratio to the Sysmex Automated Blood Coagulation Analyzer CS-5100.",
        "regulation section": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies",
        "type of test": "Quantitative clot-based applications"
    },
    "K152614.txt": {
        "510k number": "K152614",
        "applicant": "Cepheid",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as the Intended Use.",
        "intended use": "The Xpert Carba-R Assay, performed on the GeneXpert Instrument Systems, is a qualitative in vitro diagnostic test for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences associated with carbapenem-non-susceptible pure colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa grown on blood agar or MacConkey agar.",
        "measurand": "Target DNA sequence of the following genes: blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP",
        "panel": "83-Microbiology",
        "predicate 510k number": "K092953",
        "predicate device name": "Xpert vanA Assay",
        "product code": "PMY- System, nucleic acid amplification test, DNA, carbapenem non-susceptible gram negative organism, colony",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Proprietary Name: Xpert Carba-R, Common Name: Xpert Carba-R Assay",
        "purpose for submission": "To obtain a substantial equivalence determination for the Xpert Carba-R Assay on the Cepheid GeneXpert Instrument Systems",
        "regulation section": "21 CFR 866.1640 (Antimicrobial susceptibility test powder)",
        "type of test": "Qualitative real-time polymerase chain reaction (PCR) assay"
    },
    "K143736.txt": {
        "510k number": "K143736",
        "applicant": "IMMCO Diagnostics, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as intended use",
        "intended use": "Enzyme linked immunoassay (ELISA) for the qualitative or semi-quantitative detection of Rheumatoid Factor IgA, IgG, or IgM antibodies in human serum to aid in the diagnosis of rheumatoid arthritis (RA) in conjunction with other laboratory tests and clinical findings.",
        "measurand": "Rheumatoid Factors (RF) IgA, IgG, IgM, and Rheumatoid Factor Total",
        "panel": "Immunology (82)",
        "predicate 510k number": "K983084, K983083, K971614",
        "predicate device name": "Inova QuantaLite RF IgA ELISA, Inova QuantaLite RF IgG ELISA, Inova QuantaLite RF IgM ELISA",
        "product code": "DHR: System, Test, Rheumatoid Factor",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "ImmuLisa Enhanced RF IgA Antibody ELISA, ImmuLisa Enhanced RF IgG Antibody ELISA, ImmuLisa Enhanced RF IgM Antibody ELISA, ImmuLisa Enhanced RF IgA/IgG/IgM ELISA",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 866.5775: Rheumatoid factor immunological test system",
        "type of test": "Immunoassay, qualitative and semi-quantitative"
    },
    "K162705.txt": {
        "510k number": "K162705",
        "applicant": "Maine Standards Company LLC",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended use",
        "intended use": "VALIDATE D-Dimer Calibration Verification/Linearity Test Kit solutions are assayed quality control materials intended for in vitro diagnostic use in the quantitative determination of linearity, calibration verification and verification of reportable range for the following analyte: D-Dimer in a clinical laboratory setting by laboratory personnel.",
        "measurand": "D-dimer",
        "panel": "Hematology (81)",
        "predicate 510k number": "K152961",
        "predicate device name": "VALIDATE D-Dimer Calibration Verification/Linearity Test Kit",
        "product code": "GGN, Plasma, Coagulation Control",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "VALIDATE D-Dimer Calibration Verification/Linearity Test Kit",
        "purpose for submission": "To expand the use of previously cleared VALIDATE D-Dimer Calibration Verification/Linearity Test Kit to the Diagnostica Stago STA-R Evolution in combination with STA - Liatest D-Di.",
        "regulation section": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies",
        "type of test": "Quantitative"
    },
    "K192815.txt": {
        "510k number": "K192815",
        "applicant": "Roche Diagnostics",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Immunoassay for the in vitro quantitative determination of PCT (procalcitonin) in human serum and plasma (K2 \u2013EDTA, K3-EDTA and Li-Heparin).",
        "intended use": "Used in conjunction with other laboratory findings and clinical assessments, Elecsys BRAHMS PCT is intended for use as follows: to aid in the risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock, to determine the change in PCT level over time as an aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, to aid in decision making on antibiotic therapy, for inpatients or patients in the emergency department with suspected or confirmed lower respiratory tract infections (LRTI) \u2013 defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD), to aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis.",
        "measurand": "Procalcitonin (PCT)",
        "panel": "MI - Microbiology",
        "predicate 510k number": "K173927",
        "predicate device name": "Elecsys BRAHMS PCT",
        "product code": "21 CFR 866.3215",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device.",
        "proprietary and established names": "Elecsys BRAHMS PCT",
        "purpose for submission": "The purpose of this Traditional 510(k) Premarket Notification is to obtain FDA clearance for new reagents which have been added to the Elecsys BRAHMS PCT Test System.",
        "regulation section": "21 CFR 866.3215 - Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis",
        "type of test": "Quantitative, Electrochemiluminescence Immunoassay"
    },
    "K183324.txt": {
        "510k number": "K183324",
        "applicant": "ThermoFisher Scientific",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System is an in vitro diagnostic product for clinical susceptibility testing of fastidious isolates.",
        "intended use": "The Sensititre Haemophilus influenzae/Streptococcus pneumoniae plates are in vitro diagnostic products for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae, and Streptococcus species.",
        "measurand": "Omadacycline in the dilution range of 0.008 \u2013 32 \u00b5g/mL.",
        "panel": "83, Microbiology",
        "predicate 510k number": "K040846",
        "predicate device name": "Sensititre Haemophilus/Streptococcus pneumoniae (HP) MIC Plates",
        "product code": "JWY \u2013 Manual Antimicrobial Susceptibility Test System, LRG \u2013 Instrument for Auto Reader and Instrumentation of Overnight Susceptibility Systems, LTT \u2013 Panels, Test, Susceptibility, Antimicrobial",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device.",
        "proprietary and established names": "Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System with Omadacycline in the dilution range of 0.008 - 32 \u00b5g/mL",
        "purpose for submission": "To obtain a substantial equivalence determination for the addition of Omadacycline at concentrations of 0.008 \u2013 32 \u00b5g/mL to the Sensititre 20-24-hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System for testing H. influenzae and Streptococcus spp.",
        "regulation section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "type of test": "Quantitative Antimicrobial Susceptibility Test (AST), growth-based detection"
    },
    "K172745.txt": {
        "510k number": "K172745",
        "applicant": "IMMCO Diagnostics, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The ImmuGlo HEp-2 Elite IFA is an indirect immunofluorescence antibody test for the qualitative or semi-quantitative detection of anti-nuclear antibodies (ANA) of the IgG isotype in human serum utilizing standard HEp-2 cells and engineered HEp-2 cells as a substrate. The ImmuGlo HEp-2 Elite IFA is intended for use as an aid in the diagnosis of systemic rheumatic diseases in conjunction with other clinical and laboratory findings.",
        "measurand": "IgG Anti-Nuclear Antibodies (ANA)",
        "panel": "Immunology (82)",
        "predicate 510k number": "K883883",
        "predicate device name": "ImmuGlo ANTINUCLEAR ANTIBODY (ANA) TEST (HEP-2) CELLS",
        "product code": "DHN",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.",
        "proprietary and established names": "ImmuGlo HEp-2 Elite IFA",
        "purpose for submission": "New device",
        "regulation section": "21 CFR \u00a7866.5100 \u2012 Antinuclear antibody immunological test system",
        "type of test": "Qualitative or semi-quantitative, indirect immunofluorescence"
    },
    "K161510.txt": {
        "510k number": "K161510",
        "applicant": "bioM\u00e9rieux, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "VITEK 2 Gram Negative Ceftolozane/Tazobactam is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents.",
        "intended use": "The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.",
        "measurand": "The VITEK 2 AST-Gram Negative card contains the following concentrations of Ceftolozane/Tazobactam: 0.5/4, 1/4, 4/4, 8/4, and 32/4 \u00b5g/mL",
        "panel": "Microbiology (83)",
        "predicate 510k number": "K121546",
        "predicate device name": "VITEK 2 AST-GN Doxycycline",
        "product code": "LON, LTW, LTT",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "VITEK 2 AST-GN Ceftolozane/Tazobactam",
        "purpose for submission": "To obtain a substantial equivalence determination for Ceftolozane/Tazobactam for testing non-fastidious gram negative organisms on the VITEK 2 and VITEK 2 Compact Antimicrobial Susceptibility Test (AST) Systems",
        "regulation section": "21 CFR 866.1645",
        "type of test": "Automated quantitative or qualitative antimicrobial susceptibility test for Ceftolozane/Tazobactam"
    },
    "K181915.txt": {
        "510k number": "k181915",
        "applicant": "iXensor Co., LTD.",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The PixoTest POCT System, consisting of PixoTest POCT Analyzer and PixoTest A1c Test Kit, is used for the quantitative measurement of glycated hemoglobin (%HbA1c) in venous whole blood samples. It is an in-vitro diagnostic system intended to monitor long term glycemic control in individuals previously diagnosed with diabetes mellitus.",
        "intended use": "The PixoTest POCT System is intended for clinical laboratory and Point-of-Care Professional use.",
        "measurand": "Glycosylated hemoglobin (HbA1c)",
        "panel": "Hematology (81)",
        "predicate 510k number": "k140827",
        "predicate device name": "SD A1cCare System and SD A1cCare Spoit Type Test Kit",
        "product code": "LCP",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "PixoTest POCT System - PixoTest POCT Analyzer and PixoTest A1c Test Kit",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 864.7470",
        "type of test": "Quantitative Immunoassay"
    },
    "K182389.txt": {
        "510k number": "K182389",
        "applicant": "Sysmex America Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "in vitro diagnostic use in screening patient populations found in clinical laboratories",
        "intended use": "The Sysmex XN-L analyzer is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical laboratories.",
        "measurand": "WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, IG%/#, RDW-CV, RDW-SD, MPV, RET%/#, IRF, RET-He",
        "panel": "Hematology (81)",
        "predicate 510k number": "K112605",
        "predicate device name": "Sysmex XN-Series (XN-10, XN-20) Automated Hematology Analyzer",
        "product code": "GKZ",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Sysmex XN-L Automated Hematology Analyzer",
        "purpose for submission": "Expand Intended Use to include pediatric subjects under the age of 2 years old.",
        "regulation section": "21 CFR 864.5220",
        "type of test": "Automated differential cell counter"
    },
    "K183415.txt": {
        "510k number": "K183415",
        "applicant": "bioM\u00e9rieux, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "VITEK 2 AST-Gram Negative Imipenem is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents.",
        "intended use": "The VITEK 2 Gram-negative Susceptibility Card is intended for use with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram-negative bacilli to antimicrobial agents when used as instructed.",
        "measurand": "Imipenem 0.25 \u2013 16 \u00b5g/mL",
        "panel": "83 Microbiology",
        "predicate 510k number": "K172731",
        "predicate device name": "VITEK 2 AST-GN Amikacin",
        "product code": "LON \u2013 Fully automated short-term incubation cycle antimicrobial susceptibility system, LTW \u2013 Susceptibility Test Cards, Automated, LTT \u2013 Panels, Test, Susceptibility, Automated",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device",
        "proprietary and established names": "VITEK 2 AST-Gram Negative Imipenem (\u22640.25 - \u226516 \u00b5g/mL)",
        "purpose for submission": "To obtain a substantial equivalence determination for imipenem at concentrations of 0.25 \u2013 16 \u00b5g/mL for susceptibility testing of gram-negative aerobic organisms on the VITEK 2 and VITEK 2 Compact Antimicrobial Susceptibility Test (AST) Systems.",
        "regulation section": "21 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System",
        "type of test": "Automated quantitative antimicrobial susceptibility (AST)"
    },
    "K173927.txt": {
        "510k number": "K173927",
        "applicant": "Roche Diagnostics",
        "classification": "Class II (Special Controls)",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "to aid in the risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock, to determine the change in PCT level over time as an aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, to aid in decision making on antibiotic therapy, for inpatients or patients in the emergency department with suspected or confirmed lower respiratory tract infections (LRTI) \u2013 defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD), to aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis",
        "intended use": "Immunoassay for the in vitro quantitative determination of PCT (procalcitonin) in human serum and plasma (K2 \u2013EDTA, K3-EDTA and Li-Heparin)",
        "measurand": "Procalcitonin (PCT)",
        "panel": "83 - (Microbiology)",
        "predicate 510k number": "K171338",
        "predicate device name": "BRAHMS PCT sensitive KRYPTOR",
        "product code": "PMT",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device",
        "proprietary and established names": "Elecsys BRAHMS PCT",
        "purpose for submission": "To obtain a substantial equivalence determination for the Elecsys BRAHMS PCT",
        "regulation section": "21 CFR 866.3215; Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis",
        "type of test": "Quantitative, Electrochemiluminescence Immunoassay"
    },
    "K172109.txt": {
        "510k number": "K172109",
        "applicant": "Liofilchem s.r.l.",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "measurand": "Erythromycin 0.016-256 \u03bcg/mL",
        "panel": "83 \u2013 Microbiology",
        "predicate 510k number": "K153687",
        "predicate device name": "Liofilchem MTS, vancomycin",
        "product code": "JWY - Manual Antimicrobial Test Systems",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Liofilchem MIC Test Strip (MTS), Erythromycin 0.016-256 \u03bcg/mL",
        "purpose for submission": "To obtain a substantial equivalence determination for the Liofilchem MIC Test Strip (MTS) containing Erythromycin at concentrations of 0.016 -256 \u00b5g/mL for susceptibility testing of Staphylococcus aureus",
        "regulation section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "type of test": "Quantitative AST growth based detection"
    },
    "K150617.txt": {
        "510k number": "K150617",
        "applicant": "Roche Molecular Systems, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The cobas\u00ae HSV 1 and 2 Test on the cobas\u00ae 4800 system is an automated, qualitative in vitro diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection and differentiation of Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) DNA in clinician-collected, external anogenital lesion specimens from symptomatic male and female patients.",
        "measurand": "Target DNA sequences from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2)",
        "panel": "Microbiology (83)",
        "predicate 510k number": "K103798",
        "predicate device name": "BD ProbeTec\u2122 Herpes Simplex Viruses (HSV 1 & 2) Qx Amplified DNA Assays",
        "product code": "OQO",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "cobas\u00ae HSV 1 and 2 Test",
        "purpose for submission": "Clearance of New Device",
        "regulation section": "21 CFR 866.3305",
        "type of test": "An in vitro molecular diagnostic test for the qualitative detection and differentiation of HSV-1 and HSV-2 DNA in clinician-collected, external anogenital lesion specimens from symptomatic male and female patients."
    },
    "K151767.txt": {
        "510k number": "K151767",
        "applicant": "Siemens Healthcare Diagnostics Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Trinidad CH System is an automated, clinical chemistry analyzer designed to perform in vitro diagnostic tests on clinical specimens.",
        "intended use": "For in vitro diagnostic use in the quantitative determination of sodium, potassium, and chloride (Na, K, Cl) in human serum, plasma, and urine",
        "measurand": "Sodium, Potassium, Chloride, Albumin",
        "panel": "Clinical Chemistry",
        "predicate 510k number": "K990346, K132664",
        "predicate device name": "Siemens ADVIA 1800 Chemistry System including ISE and Albumin BCP Assays",
        "product code": "JGS, CEM, CGZ, CJW, JIT, JIX, JJE",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Trinidad CH system, TD-LYTE Integrated Multisensor (Na, K, Cl), TD-LYTE IMT Standard A, TD-LYTE IMT Standard B + Salt Bridge, Trinidad CH Albumin BCP Reagent (Alb_P), Trinidad CH Albumin BCP Calibrator",
        "purpose for submission": "New devices",
        "regulation section": "21 CFR 862.1665, 21 CFR 862.1600, 21 CFR 862.1170, 21 CFR 862.1035, 21 CFR 862.1150, 21 CFR 862.2160",
        "type of test": "Quantitative, photometry, and ion selective multisensors for electrolytes"
    },
    "K150144.txt": {
        "510k number": "K150144",
        "applicant": "Affinity Biologicals Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as intended use",
        "intended use": "The VisuCon-F Low Fibrinogen Control Plasma is an assayed control plasma prepared from de-fibrinated human plasma intended for use in the quality control of quantitative fibrinogen assays in the low abnormal range.",
        "measurand": "Fibrinogen",
        "panel": "81 (Hematology)",
        "predicate 510k number": "K951823",
        "predicate device name": "Precision Biologic Inc., Cryocheck Low Fibrinogen Control",
        "product code": "GGN, Plasma, Coagulation Control",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "VisuCon-F Low Fibrinogen Control Plasma",
        "purpose for submission": "Clearance of a new device",
        "regulation section": "21 CFR \u00a7864.5425, Multipurpose system for in vitro coagulation studies",
        "type of test": "Quality Control Material, Assayed"
    },
    "K153137.txt": {
        "510k number": "K153137",
        "applicant": "Instrumentation Laboratory (IL) Co.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "HemosIL HIT-Ab(PF4-H) is a qualitative, fully automated, latex enhanced immunoassay for the detection of anti-platelet factor 4/heparin (PF4/H) antibodies.",
        "measurand": "Anti-PF4/Heparin Total Antibodies",
        "panel": "Hematology (81)",
        "predicate 510k number": "K003767",
        "predicate device name": "Asserachrom HPIA Test kit",
        "product code": "LCO, Platelet factor 4 radioimmunoassay, GGN, Plasma, Coagulation Control",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "HemosIL HIT\u2010Ab(PF4\u2010H), HemosIL HIT\u2010Ab(PF4\u2010H) Controls",
        "purpose for submission": "Clearance of a new device",
        "regulation section": "21 CFR 864.7695, Platelet factor 4 radioimmunoassay, 21 CFR 864.5425, Multipurpose system for in vitro coagulation studies",
        "type of test": "Automated, latex enhanced immuno-turbidimetric assay"
    },
    "K170127.txt": {
        "510k number": "K170127",
        "applicant": "Hardy Diagnostics",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Use of HardyDisk Ceftolozane/Tazobactam, (30/10\u00b5g) - C/T40, for in vitro agar diffusion susceptibility testing is indicated when there is a need to determine the susceptibility of bacteria to Ceftolozane/Tazobactam.",
        "intended use": "HardyDisk AST Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens.",
        "measurand": "Ceftolozane/Tazobactam, 30/10\u00b5g",
        "panel": "83 - Microbiology",
        "predicate 510k number": "K062245",
        "predicate device name": "HardyDisk Tigecycline 15\u00b5g",
        "product code": "JTN \u2013 Susceptibility Test Disc, Antimicrobial",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "HardyDisk Ceftolozane/Tazobactam, (30/10\u00b5g) - C/T40",
        "purpose for submission": "Addition of Ceftolozane/Tazobactam Antimicrobial Susceptibility Test Disk for testing Enterobacteriaceae",
        "regulation section": "21 CFR 866.1620 Antimicrobial Susceptibility Test Disc",
        "type of test": "Antimicrobial Susceptibility Test Disks"
    },
    "K143548.txt": {
        "510k number": "k143548",
        "applicant": "Trividia Health, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The TRUE METRIX GO Self Monitoring Blood Glucose System is intended for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip.",
        "intended use": "The TRUE METRIX GO Self Monitoring Blood Glucose System is intended to be used by a single person and not shared. The TRUE METRIX GO Self Monitoring Blood Glucose System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control.",
        "measurand": "Capillary whole blood glucose from the fingertip",
        "panel": "Clinical Chemistry (75)",
        "predicate 510k number": "k062058",
        "predicate device name": "Bayer Ascensia Contour Blood Glucose Monitoring System",
        "product code": "NBW, System, Test, Blood Glucose, Over the Counter, LFR, Glucose Dehydrogenase, Glucose",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "TRUE METRIX\u2122 GO Blood Glucose Monitoring System",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 862.1345, Glucose test system",
        "type of test": "Quantitative Amperometric assay (FAD-Glucose Dehydrogenase)"
    },
    "K163517.txt": {
        "510k number": "K163517",
        "applicant": "Liofilchem s.r.l.",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of non-fastidious Gram negative and Gram positive aerobic bacteria (for example, Enterobacteriaceae, Pseudomonas, Enterococcus and Staphylococcus species) and fastidious bacteria (for example, anaerobes, Haemophilus and Streptococcus species and N. gonorrhoeae).",
        "intended use": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of non-fastidious Gram negative and Gram positive aerobic bacteria (for example, Enterobacteriaceae, Pseudomonas, Enterococcus and Staphylococcus species) and fastidious bacteria (for example, anaerobes, Haemophilus and Streptococcus species and N. gonorrhoeae).",
        "measurand": "Telavancin 0.016 \u2013 256 \u00b5g/mL",
        "panel": "83 \u2013 Microbiology",
        "predicate 510k number": "K153687",
        "predicate device name": "Liofilchem MIC Test Strip (MTS) \u2013 Vancomycin 0.016 \u2013 256 \u03bcg/mL",
        "product code": "JWY \u2013 Manual Antimicrobial Test Systems",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Liofilchem MIC Test Strip (MTS), Telavancin 0.016 \u2013 256 \u03bcg/mL",
        "purpose for submission": "To obtain a substantial equivalence determination for the Liofilchem MIC Test Strip (MTS) containing Telavancin in concentrations of 0.016 \u2013 256 \u00b5g/mL for susceptibility testing of Staphylococcus aureus (including methicillin-resistant isolates) and Enterococcus faecalis (vancomycin-susceptible isolates only).",
        "regulation section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "type of test": "Quantitative AST growth based detection"
    },
    "K152495.txt": {
        "510k number": "k152495",
        "applicant": "Guangzhou Wondfo Biotech Co., Ltd.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Wondfo Propoxyphene Urine Test is an immunochromatographic assay for the qualitative determination of d-Propoxyphene in human urine at a cutoff concentration of 300 ng/mL.",
        "intended use": "For prescription use and over the counter use.",
        "measurand": "Propoxyphene",
        "panel": "Toxicology, 91",
        "predicate 510k number": "k121557",
        "predicate device name": "Wondfo Propoxyphene Urine Test",
        "product code": "JXN",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Wondfo Propoxyphene Urine Test",
        "purpose for submission": "Addition of an over-the-counter (OTC) claim",
        "regulation section": "21 CFR \u00a7862.3700",
        "type of test": "Qualitative immunochromatographic assay"
    },
    "K181324.txt": {
        "510k number": "K181324",
        "applicant": "BioFire Diagnostics, LLC",
        "classification": "Class II (Special Controls)",
        "conclusion": "The FilmArray Pneumonia Panel plus is substantially equivalent to the predicate device, FilmArray Respiratory Panel 2 plus (RP2plus) (DEN170017)",
        "indications for use": "The FilmArray Pneumonia Panel plus is a multiplexed nucleic acid test intended for use with FilmArray, FilmArray 2.0, or FilmArray Torch systems for the simultaneous detection and identification of multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes, in sputum-like specimens (induced or expectorated sputum, or endotracheal aspirates) or bronchoalveolar lavage (BAL)-like specimens (BAL or mini-BAL) obtained from individuals meeting MERS-CoV clinical and/or epidemiological criteria",
        "intended use": "The FilmArray Pneumonia Panel plus is a multiplexed nucleic acid test intended for use with FilmArray, FilmArray 2.0, or FilmArray Torch systems for the simultaneous detection and identification of multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes, in sputum-like specimens (induced or expectorated sputum, or endotracheal aspirates) or bronchoalveolar lavage (BAL)-like specimens (BAL or mini-BAL) obtained from individuals meeting MERS-CoV clinical and/or epidemiological criteria",
        "measurand": "Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae complex, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae group, Moraxella catarrhalis, Proteus spp., Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, Adenovirus, Coronavirus, Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, Influenza B, Middle East Respiratory Syndrome Coronavirus, Parainfluenza Virus, Respiratory Syncytial Virus, CTX-M, IMP, KPC, NDM, OXA-48-like, VIM, mecA/C and MREJ",
        "panel": "83-Microbiology",
        "predicate 510k number": "DEN170017",
        "predicate device name": "FilmArray Respiratory Panel 2 plus (RP2plus)",
        "product code": "PZF",
        "proposed labeling": "Same as Intended Use",
        "proprietary and established names": "FilmArray Pneumonia Panel plus",
        "purpose for submission": "To obtain a substantial equivalence determination for the FilmArray Pneumonia Panel plus",
        "regulation section": "21 CFR 866.4001 \u2013 MERS-CoV and common respiratory pathogens multiplex nucleic acid detection system",
        "type of test": "Qualitative and quantitative nucleic acid amplification assay"
    },
    "K162840.txt": {
        "510k number": "k162840",
        "applicant": "Roche Diagnostics",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "The Elecsys Vitamin D total II assay is intended for the quantitative determination of total 25-hydroxyvitamin D in human serum and plasma",
        "intended use": "This assay is to be used as an aid in the assessment of vitamin D sufficiency in adults",
        "measurand": "Total 25-hydroxyvitamin D (25-OH vitamin D)",
        "panel": "Clinical Chemistry (75)",
        "predicate 510k number": "k113546",
        "predicate device name": "Elecsys Vitamin D Assay",
        "product code": "MRG \u2013 Vitamin D Test System, JIT \u2013 Calibrator, secondary, JJX \u2013 Quality Control Material",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "Elecsys Vitamin D total II, Vitamin D total II CalSet, PreciControl Vitamin D total II, Vitamin D CalCheck",
        "purpose for submission": "New Device",
        "regulation section": "21 CFR 862.1825, Vitamin D Test System, 21 CFR 862.1150, Calibrator, 21 CFR 862.1660, Quality Control Material (assayed and unassayed)",
        "type of test": "Quantitative electrochemiluminescence immunoassay"
    },
    "K173887.txt": null,
    "K162895.txt": {
        "510k number": "K162895",
        "applicant": "Roche Diagnostics",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "for the in vitro quantitative determination of cardiac troponin T (cTnT) in lithium heparin plasma. The immunoassay is intended to aid in the diagnosis of myocardial infarction.",
        "intended use": "See Indication(s) for use.",
        "measurand": "Cardiac troponin T (cTnT)",
        "panel": "Chemistry",
        "predicate 510k number": "K051752, K961500, K082699, K122242",
        "predicate device name": "Elecsys Troponin T STAT Assay, Elecsys Troponin T CalSet, Elecsys PreciControl Troponin, Elecsys CA 15-3 CalCheck 5",
        "product code": "JIT, JJX, JJY",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Elecsys Troponin T Gen 5 STAT Immunoassay, Elecsys Troponin T Gen 5 STAT CalSet, Elecsys PreciControl Troponin, Elecsys Troponin T Gen 5 CalCheck 5",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 862.1215 - Creatine phosphokinase/creatine kinase or isoenzymes test system, 21 CFR 862.1150 - Calibrator, 21 CFR 862.1660 - Quality control material (assayed and unassayed)",
        "type of test": "Quantitative immunoassay"
    },
    "K180264.txt": {
        "510k number": "K180264",
        "applicant": "Gold Standard Diagnostics",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit is intended as a qualitative presumptive (first-step) test for the detection of IgG and IgM antibodies to B. burgdorferi sensu stricto in human serum from symptomatic patients or people suspected of infection.",
        "measurand": "Anti-Borrelia burgdorferi (IgM and IgG) antibodies",
        "panel": "Microbiology",
        "predicate 510k number": "K033070",
        "predicate device name": "Trinity Biotech Captia Borrelia burgdorferi IgG/IgM ELISA Test Kit",
        "product code": "LSR",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.",
        "proprietary and established names": "Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit",
        "purpose for submission": "To obtain a substantial equivalence determination and FDA clearance for a new device.",
        "regulation section": "21 CFR 866.3830",
        "type of test": "Enzyme Immunoassay"
    },
    "K160682.txt": {
        "510k number": "k160682",
        "applicant": "Ascensia Diabetes Care",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Contour Next ONE blood glucose monitoring system is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertips or palm.",
        "intended use": "The Contour Next ONE blood glucose monitoring system is intended to be used by a single person and should not be shared. The Contour Next ONE blood glucose monitoring system is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program.",
        "measurand": "Glucose in fresh capillary whole blood from the fingertip and palm.",
        "panel": "75, Clinical Chemistry",
        "predicate 510k number": "k150942",
        "predicate device name": "CONTOUR NEXT USB Blood Glucose Meter",
        "product code": "NBW, Blood glucose test system, over the counter, LFR, Glucose Dehydrogenase, Glucose",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "CONTOUR NEXT ONE Blood Glucose Monitoring System",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 862.1345",
        "type of test": "Quantitative, Amperometric method, Glucose dehydrogenase (FAD)"
    },
    "K181092.txt": {
        "510k number": "K181092",
        "applicant": "bioM\u00e9rieux SA",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "CHROMID CARBA agar is a selective and differential chromogenic medium that is intended for the qualitative detection and presumptive identification of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in rectal swab specimens from patients at risk of colonization.",
        "measurand": "Colonies of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae",
        "panel": "83: Microbiology",
        "predicate 510k number": "K091025",
        "predicate device name": "bioM\u00e9rieux CHROMID VRE agar",
        "product code": "JSO: Culture Media, Antimicrobial Susceptibility Test, Excluding Mueller Hinton Agar",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device.",
        "proprietary and established names": "CHROMID CARBA agar (CARB)",
        "purpose for submission": "To obtain a substantial equivalence determination for the CHROMID CARBA Agar",
        "regulation section": "21 CFR 866.1700: Culture medium for antimicrobial susceptibility tests",
        "type of test": "Selective and differential culture medium"
    },
    "K170464.txt": {
        "510k number": "k170464",
        "applicant": "Nova Biomedical Corporation",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The StatStrip Xpress Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood as an aid to monitor the effectiveness of diabetes control in people with diabetes.",
        "intended use": "The StatStrip Xpress Blood Glucose Monitoring System is intended for single-patient home use and should not be shared. It is intended for self-testing outside the body by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control.",
        "measurand": "Fresh capillary whole blood glucose from the fingertip",
        "panel": "Clinical Chemistry (75)",
        "predicate 510k number": "k160156",
        "predicate device name": "StatStrip Xpress Blood Glucose Monitoring System",
        "product code": "NBW, System, Test, Blood Glucose, Over The Counter",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "StatStrip Xpress Blood Glucose Monitoring System",
        "purpose for submission": "This submission seeks changes in labeling for the previously cleared StatStrip Xpress Blood Glucose Monitoring System (k160156).",
        "regulation section": "21 CFR 862.1345, Glucose test system",
        "type of test": "Quantitative, amperometric assay (Glucose Oxidase)"
    },
    "K150041.txt": {
        "510k number": "K150041",
        "applicant": "Coramed Technologies, LLC",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The indication for CORA System use is with adult patients where an evaluation of their blood hemostasis properties is desired.",
        "intended use": "The CORA System is intended for in vitro diagnostic use to provide semi-quantitative indications of the hemostasis state of a blood sample.",
        "measurand": "Coagulation factors (intrinsic and extrinsic pathway) and platelet aggregation",
        "panel": "Hematology (81)",
        "predicate 510k number": "K002177",
        "predicate device name": "Thromboelastograph Coagulation Analyzer (TEG)-5000 Series, Haemoscope Corporation",
        "product code": "JPA, System, Multipurpose For In Vitro Coagulation Control, GGN, Plasma, Coagulation Control",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "CORA (Coagulation Resonance Analysis) System",
        "purpose for submission": "Clearance of a new device",
        "regulation section": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies, 21 CFR 864.5700, Automated platelet aggregation system",
        "type of test": "Whole blood hemostasis"
    },
    "K181043.txt": {
        "510k number": "k181043",
        "applicant": "Nova Biomedical Corporation",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The StatStrip Glucose Hospital Meter System is intended for point-of-care, in vitro diagnostic, multiple-patient use for the quantitative determination of glucose in capillary finger stick, venous whole blood, arterial whole blood, neonate arterial whole blood and neonate heel stick specimens throughout all hospital and all professional healthcare settings including patients receiving intensive medical intervention/therapy.",
        "intended use": "The StatStrip Glucose Hospital Meter System is intended for point-of-care, in vitro diagnostic, multiple-patient use for the quantitative determination of glucose in capillary finger stick, venous whole blood, arterial whole blood, neonate arterial whole blood and neonate heel stick specimens throughout all hospital and all professional healthcare settings including patients receiving intensive medical intervention/therapy.",
        "measurand": "Capillary whole blood glucose",
        "panel": "Clinical Chemistry",
        "predicate 510k number": "k150281",
        "predicate device name": "Nova StatStrip Glucose Hospital Meter System",
        "product code": "PZI",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirement of 21 CFR Part 809.10.",
        "proprietary and established names": "StatStrip Glucose Hospital Meter System",
        "purpose for submission": "This submission is a Dual 510(k) and CLIA Waiver by Application (Dual Submission) tracked as k181043 and CW180005.",
        "regulation section": "21 CFR 862.1345",
        "type of test": "Quantitative amperometric assay, glucose oxidase"
    },
    "K161714.txt": {
        "510k number": "k161714",
        "applicant": "Immunalysis Corporation",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Immunalysis Barbiturates Urine Enzyme Immunoassay is a homogeneous enzyme immunoassay with a cutoff of 200 ng/mL. The assay is intended for use in laboratories for the qualitative and semi-quantitative analysis of Barbiturates in human urine with automated clinical chemistry analyzers.",
        "intended use": "Refer to Indications for Use below",
        "measurand": "Barbiturates",
        "panel": "Toxicology (91)",
        "predicate 510k number": "k955928",
        "predicate device name": "DRI Barbiturates EIA Assay",
        "product code": "DIS, DKB",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Immunalysis Barbiturates Urine Enzyme Immunoassay, Immunalysis Multi-Drug Calibrators",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 862.3150 Barbiturate test system, 21 CFR 862.3200, Clinical toxicology calibrator",
        "type of test": "Homogenous Enzyme Immunoassay, Qualitative and Semi-quantitative"
    },
    "K142965.txt": {
        "510k number": "k142965",
        "applicant": "Ventana Medical Systems, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The CONFIRM\u2122 anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay is indicated for use as an aid in the assessment of breast cancer patients for whom endocrine treatment is being considered",
        "intended use": "The VirtuosoTM System for IHC PR (1E2) using the VENTANA iScan HT is for the digital read application. This particular Virtuoso system is intended for use as an aid to the pathologist in the qualitative detection of progesterone receptor (PR) protein in formalin-fixed, paraffin-embedded normal and neoplastic tissue.",
        "measurand": "Progesterone Receptor (PR) protein",
        "panel": "Pathology (88)",
        "predicate 510k number": "k111869",
        "predicate device name": "Virtuoso\u2122 System for IHC PR (1E2)",
        "product code": "OEO",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "VirtuosoTM System for IHC PR (1E2), CONFIRM\u2122 anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody",
        "purpose for submission": "New device",
        "regulation section": "21 CFR \u00a7864.1860",
        "type of test": "Manual scoring of digital images on a computer monitor of progesterone receptor (PR) (1E2) immunohistochemistry (IHC) stained slides using the VENTANA iScan HT scanner."
    },
    "K181889.txt": {
        "510k number": "K181889",
        "applicant": "Liofilchem s.r.l.",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The Liofilchem MTS (MIC Test Strip) Penicillin 0.002-32 \u03bcg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "measurand": "Penicillin 0.002-32 \u03bcg/mL",
        "panel": "83 \u2013 Microbiology",
        "predicate 510k number": "K153687",
        "predicate device name": "Liofilchem MTS, vancomycin",
        "product code": "JWY - Manual Antimicrobial Susceptibility Test Systems",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device.",
        "proprietary and established names": "MTS Penicillin 0.002-32 \u03bcg/mL",
        "purpose for submission": "To obtain a substantial equivalence determination for Penicillin (P) at concentrations of 0.002-32 \u00b5g/mL for susceptibility testing of fastidious Gram-positive organisms",
        "regulation section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "type of test": "Quantitative Antimicrobial Susceptibility Test growth-based detection"
    },
    "K181288.txt": {
        "510k number": "K181288",
        "applicant": "Athelas Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as intended use",
        "intended use": "Athelas One is indicated for use for quantitative determination of white blood cells (WBC) and Neutrophil percentages (NEUT%) in capillary or K2EDTA venous whole blood.",
        "measurand": "White blood cell count (WBC) and percent neutrophil count (NEUT%)",
        "panel": "Hematology (81)",
        "predicate 510k number": "K071967",
        "predicate device name": "Sysmex XE-5000 Automated Hematology Analyzer",
        "product code": "GKZ, Counter, differential cell",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.",
        "proprietary and established names": "Athelas One",
        "purpose for submission": "Clearance of a new device",
        "regulation section": "21 CFR 864.5220, Automated differential cell counter",
        "type of test": "Enumeration of WBCs and NEUT%"
    },
    "K183462.txt": {
        "510k number": "K183462",
        "applicant": "MRIGlobal",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "Same as Intended Use",
        "intended use": "The Applied Biosystems Bacillus anthracis Detection Kit is a real-time polymerase chain reaction (PCR) test kit intended for the qualitative in vitro diagnostic (IVD) detection of target DNA sequences for Bacillus anthracis (B. anthracis, or BA).",
        "measurand": "Nucleic acid sequences of Bacillus anthracis pX01 and pX02 plasmids",
        "panel": "83- Microbiology",
        "predicate 510k number": "DEN160048",
        "predicate device name": "FilmArray NGDS Warrior Panel",
        "product code": "QIF, OOI",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device",
        "proprietary and established names": "Applied Biosystems Bacillus anthracis Detection Kit, Applied Biosystems (AB) 7500 Fast Dx",
        "purpose for submission": "Clearance of the Applied Biosystems Bacillus anthracis Detection Kit on the Applied Biosystems (AB) 7500 Fast Dx instrument and Applied Biosystems Bacillus anthracis Interpretive Software (BaIS).",
        "regulation section": "CFR 866.4000",
        "type of test": "Real-time polymerase chain reaction"
    },
    "K180936.txt": {
        "510k number": "K180936",
        "applicant": "bioM\u00e9rieux, Inc.",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as the Intended Use",
        "intended use": "ETEST is a quantitative technique for determination of antimicrobial susceptibility of non-fastidious Gram-negative and Gram-positive aerobic bacteria",
        "measurand": "Telavancin 0.002 \u2013 32 \u00b5g/mL",
        "panel": "83 \u2013Microbiology",
        "predicate 510k number": "K151873",
        "predicate device name": "ETEST Ceftaroline",
        "product code": "JWY \u2013 Manual Antimicrobial Test Systems",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device.",
        "proprietary and established names": "ETEST Telavancin (TLA) (0.002 \u2013 32 \u00b5g/mL)",
        "purpose for submission": "To obtain a substantial equivalence determination for telavancin at concentrations of 0.002 \u2013 32 \u00b5g/mL for susceptibility testing of Gram positive aerobic microorganisms with ETEST.",
        "regulation section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "type of test": "Quantitative AST growth-based detection"
    },
    "K143329.txt": {
        "510k number": "K143329",
        "applicant": "Quidel Corporation",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The AmpliVue Trichomonas Assay is an in vitro diagnostic test, uses isothermal amplification technology (helicase-dependent amplification, HDA) for the qualitative detection of Trichomonas vaginalis nucleic acids isolated from clinician-collected vaginal swab specimens obtained from symptomatic or asymptomatic females to aid in the diagnosis of trichomoniasis.",
        "measurand": "A conserved multi-copy sequence of Trichomonas vaginalis genomic DNA",
        "panel": "83 - Microbiology",
        "predicate 510k number": "K122062",
        "predicate device name": "APTIMA Trichomonas vaginalis Assay (PANTHER System)",
        "product code": "OUY - Trichomonas vaginalis nucleic acid amplification test system",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Amplivue Trichomonas Assay",
        "purpose for submission": "To obtain clearance for a new device, Amplivue Trichomonas Assay",
        "regulation section": "21 CFR 866.3860",
        "type of test": "Nucleic acid amplification assay (Helicase-dependent Amplification, HDA)"
    },
    "K181379.txt": {
        "510k number": "K181379",
        "applicant": "TechLab Inc.",
        "classification": "Class I",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The same as the Intended Use",
        "intended use": "The TECHLAB H. PYLORI QUIK CHEK test is a rapid membrane enzyme immunoassay for the qualitative detection of Helicobacter pylori specific antigen in a single use cassette.",
        "measurand": "H. pylori antigen",
        "panel": "2 83-Microbiology",
        "predicate 510k number": "K032222",
        "predicate device name": "ImmunoCard STAT! HpSA",
        "product code": "LYR",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device.",
        "proprietary and established names": "H. PYLORI QUIK CHEK",
        "purpose for submission": "To obtain a substantial equivalence determination for the detection of Helicobacter pylori antigens in human stool.",
        "regulation section": "21 CFR 866.3110",
        "type of test": "Qualitative membrane enzyme immunoassay"
    },
    "K190219.txt": {
        "510k number": "K190219",
        "applicant": "DiaSorin",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The DiaSorin Molecular Simplexa VZV Direct assay is intended for use on the LIAISON MDX instrument for the qualitative detection of varicella-zoster virus (VZV) DNA in cerebrospinal fluid (CSF) from patients with signs and/or symptoms of meningitis and/or encephalitis.",
        "measurand": "Varicella zoster virus DNA",
        "panel": "MI - Microbiology",
        "predicate 510k number": "K160462",
        "predicate device name": "FilmArray Meningitis/Encephalitis (ME) Panel for use with FilmArray and FilmArray 2.0 systems",
        "product code": "PLO",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.",
        "proprietary and established names": "Simplexa VZV Direct, Simplexa VZV Positive Control Pack",
        "purpose for submission": "Clearance of device to detect and identify Varizella Zoster Virus DNA in cerebrospinal fluid",
        "regulation section": "21 CFR 866.3970 - Device to detect and identify microbial pathogen nucleic acids in cerebrospinal fluid",
        "type of test": "Realtime Polymerase Chain Reaction"
    },
    "K151265.txt": {
        "510k number": "K151265",
        "applicant": "SD Biosensor Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The SD GlucoNFC Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood from fingertip, palm, forearm or upper arm.",
        "intended use": "for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control",
        "measurand": "Capillary whole blood glucose from fingertip, palm, forearm, or upper arm.",
        "panel": "(75) Chemistry",
        "predicate 510k number": "K123517",
        "predicate device name": "SD GlucoMentor BGMS",
        "product code": "NBW - System, Test, Blood Glucose, Over-the-Counter",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "SD GlucoNFC Blood Glucose Monitoring System, SD GlucoNFC Multi Blood Glucose Monitoring System",
        "purpose for submission": "New Submission",
        "regulation section": "862.1345, Glucose Test System, 862.1660, Quality control material (assayed and unassayed)",
        "type of test": "Quantitative Amperometric Assay; glucose dehydrogenase - flavin adenine dinucleotide (GDH-FAD)"
    },
    "K181700.txt": {
        "510k number": "K181700",
        "applicant": "Hardy Diagnostics",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Use of HardyDisk AST Plazomicin 30\u00b5g (PLZ30) for in vitro agar diffusion susceptibility testing is indicated when there is need to determine the susceptibility of bacteria to Plazomicin.",
        "intended use": "HardyDisk AST Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens.",
        "measurand": "Plazomicin 30\u00b5g",
        "panel": "83, Microbiology",
        "predicate 510k number": "K062245",
        "predicate device name": "HardyDisk Tigecycline 15\u00b5g",
        "product code": "JTN",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device.",
        "proprietary and established names": "HardyDisk AST Plazomicin 30\u00b5g (PLZ30)",
        "purpose for submission": "Addition of Plazomicin Antimicrobial Susceptibility Test Disk",
        "regulation section": "21 CFR 866.1620 Antimicrobial Susceptibility Test Disc",
        "type of test": "Antimicrobial Susceptibility Test Disks"
    },
    "K171971.txt": {
        "510k number": "k171971",
        "applicant": "Lite-On Technology Corp.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Comprehensive Metabolic Panel is intended to be used for the quantitative determination of Alkaline Phosphate (ALP), Alanine Aminotransferase (ALP/GPT), Aspartate Aminotransferase (AST/GOT), Blood Urea Nitrogen (BUN) and Creatinine (CREA) in concentrations in lithium-heparinized venous whole blood, heparinized plasma, or serum in a clinical laboratory setting or point-of-care location.",
        "intended use": "An in-vitro diagnostic device for the quantitative determination of clinical chemistry analytes in lithium-heparinized venous whole blood, heparinized plasma, or serum. It is for clinical laboratory and point-of-care use.",
        "measurand": "Alkaline phosphate (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Blood urea nitrogen (BUN) and Creatinine (CREA)",
        "panel": "Comprehensive Metabolic Panel",
        "predicate 510k number": "k942782, k950164",
        "predicate device name": "Abaxis Piccolo, Abaxis Piccolo Primary Health Panel Reagent Rotor",
        "product code": "CJE, CDN, CGX, CIT, CKA, JJG",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.",
        "proprietary and established names": "Comprehensive Metabolic Panel, skyla Clinical Chemistry Analyzer, Minicare C300 Clinical Chemistry Analyzer",
        "purpose for submission": "New Device",
        "regulation section": "862.1050, 862.1770, 862.1225, 862.1100, 862.1030, 862.2160",
        "type of test": "Quantitative, photometric/colorimetric"
    },
    "K173829.txt": {
        "510k number": "k173829",
        "applicant": "Wallac Oy, a subsidiary of PerkinElmer",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The NeoLSD MSMS Kit is intended for the quantitative measurement of the activity of the enzymes acid-\u03b2-glucocerebrosidase (ABG), acid-sphingomyelinase (ASM), acid-\u03b1-glucosidase (GAA), \u03b2-galactocerebrosidase (GALC), \u03b1-galactosidase A (GLA), and \u03b1-L-iduronidase (IDUA) in dried blood spots (DBS) from newborn babies.",
        "intended use": "The analysis of the enzymatic activity is intended as an aid in screening newborns for the following lysosomal storage disorders (LSD) respectively; Gaucher Disease, Niemann-Pick A/B Disease, Pompe Disease, Krabbe Disease, Fabry Disease, and mucopolysaccharidosis Type I (MPS I) Disease.",
        "measurand": "Acid-\u03b2-glucocerebrosidase (ABG), acid-sphingomyelinase (ASM), acid-\u03b1-glucosidase (GAA), \u03b2-galactocerebrosidase (GALC), \u03b1-galactosidase A (GLA), \u03b1-L-iduronidase (IDUA)",
        "panel": "Chemistry (75)",
        "predicate 510k number": "DEN150035",
        "predicate device name": "SEEKER System",
        "product code": "PQW, PQT, PQV, QCL, QCM",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable and the special controls for this device type under 21 CFR 862.1488.",
        "proprietary and established names": "NeoLSD MSMS kit",
        "purpose for submission": "New device",
        "regulation section": "862.1488 Lysosomal storage disorder newborn screening test system",
        "type of test": "Quantitative mass spectrometric enzymatic activity assay"
    },
    "K150168.txt": {
        "510k number": "k150168",
        "applicant": "Siemens Healthcare Diagnostics, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Dimension Tacrolimus Flex Reagent Cartridge (TAC) is an in vitro diagnostic test for the quantitative measurement of tacrolimus in human whole blood on the Dimension clinical chemistry system. Measurements of tacrolimus are used as an aid in the management of tacrolimus therapy in renal and hepatic transplant patients.",
        "intended use": "See indications for use below.",
        "measurand": "Tacrolimus",
        "panel": "Toxicology (91)",
        "predicate 510k number": "k070820",
        "predicate device name": "ARCHITECT Tacrolimus Assay",
        "product code": "MLM, JIT",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Dimension Tacrolimus Flex Reagent Cartridge (TAC), Dimension Tacrolimus Calibrator (TAC CAL)",
        "purpose for submission": "New Device",
        "regulation section": "21 CFR 862.1678, Tacrolimus Test System, 21 CFR 862.1150, Calibrator",
        "type of test": "Quantitative immunoassay"
    },
    "K173817.txt": {
        "510k number": "K173817",
        "applicant": "Liofilchem s.r.l.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "Same as Intended Use",
        "intended use": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria",
        "measurand": "Ceftazidime/avibactam 0.016/4 \u2013 256/4 \u00b5g/mL",
        "panel": "Microbiology (83)",
        "predicate 510k number": "K153687",
        "predicate device name": "Liofilchem MTS, Vancomycin",
        "product code": "JWY \u2013 Manual Antimicrobial Test Systems",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "Liofilchem MIC Test Strip (MTS), Ceftazidime-avibactam 0.016/4 \u2013 256/4 \u00b5g/mL",
        "purpose for submission": "To obtain a substantial equivalence determination of the Liofilchem MIC Test Strip (MTS) containing Ceftazidime/avibactam",
        "regulation section": "21 CFR 866.1640 Antimicrobial Susceptibility Test Powder",
        "type of test": "Quantitative Antimicrobial Susceptibility Test growth based detection"
    },
    "K150588.txt": {
        "510k number": "K150588",
        "applicant": "Vermillion, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended use",
        "intended use": "The OVA1 Next Generation test is a qualitative serum test that combines the results of five immunoassays into a single numeric result. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist.",
        "measurand": "Score based on 5 serum analytes",
        "panel": "Immunology (82)",
        "predicate 510k number": "K081754",
        "predicate device name": "Vermillion OVA1",
        "product code": "ONX, Serum, algorithm, ovarian cancer assessment test",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "OVA1 Next Generation",
        "purpose for submission": "New device",
        "regulation section": "21 CFR \u00a7866.6050, Ovarian adnexal mass assessment score test system",
        "type of test": "Software algorithm that combines five immunoassays into a single score"
    },
    "K193024.txt": {
        "510k number": "K193024",
        "applicant": "Thermo Fisher Scientific",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "The Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System is an in vitro diagnostic product for clinical susceptibility testing of H. influenzae, Streptococcus pneumoniae, and Streptococcus spp",
        "intended use": "See Indications for Use below",
        "measurand": "Lefamulin in the dilution range of 0.008 \u2013 16 \u03bcg/mL",
        "panel": "MI - Microbiology",
        "predicate 510k number": "K183324",
        "predicate device name": "Sensititre 20-24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System with Omadacycline in the dilution range of 0.008 - 32 ug/mL",
        "product code": "JWY, LRG, LTT",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device",
        "proprietary and established names": "Sensititre 20-24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint, Susceptibility System with Lefamulin in the dilution range of 0.008-16 \u00b5g/mL",
        "purpose for submission": "To obtain a substantial equivalence determination for the addition of Lefamulin to the Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint, Susceptibility System with Lefamulin in the dilution range of 0.008 \u2013 16 ug/mL",
        "regulation section": "21 CFR 866.1640 - Antimicrobial Susceptibility Test Powder",
        "type of test": "Quantitative Antimicrobial Susceptibility Test (AST), growth-based detection"
    },
    "K141114.txt": {
        "510k number": "k141114",
        "applicant": "Bio-Rad Laboratories",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "The BioPlex 2200 25-OH Vitamin D kit is a flow competitive immunoassay intended for the quantitative determination of 25-hydroxyvitamin D in human serum",
        "intended use": "For in vitro diagnostics, For prescription use only",
        "measurand": "25-hydroxyvitamin D [25(OH) Vitamin D]",
        "panel": "Chemistry (75)",
        "predicate 510k number": "k123660",
        "predicate device name": "EUROIMMUN 25-OH Vitamin D ELISA",
        "product code": "MRG, JIT, JJX",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "BioPlex 2200 25-OH Vitamin D Kit, BioPlex 2200 25-OH Vitamin D Calibrator Set, BioPlex 2200 25-OH Vitamin D Control Set",
        "purpose for submission": "New Device",
        "regulation section": "862.1825 Vitamin D Test System, 862.1150 Calibrator, 862.1660 Quality Control Material (Assayed and Unassayed)",
        "type of test": "Quantitative multiplexed flow immunoassay"
    },
    "K153683.txt": {
        "510k number": "K153683",
        "applicant": "Sandstone Diagnostics, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The Trak Male Fertility Testing System is intended for semi-quantitative assessment of sperm concentration at 15 million sperm per milliliter (M/mL) or below, between 15 and 55 M/mL, and above 55 M/mL.",
        "measurand": "Sperm concentration",
        "panel": "Hematology (81)",
        "predicate 510k number": "K100341",
        "predicate device name": "SpermCheck Fertility",
        "product code": "GKZ",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Trak Male Fertility Testing System",
        "purpose for submission": "Clearance of a new device",
        "regulation section": "21 CFR 864.5220",
        "type of test": "Centrifuged packed cell height via density gradient separation"
    },
    "K161217.txt": {
        "510k number": "K161217",
        "applicant": "bioM\u00e9rieux, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "VITEK\u00ae2 Gram Negative Ceftriaxone is designed for antimicrobial susceptibility testing of Gram negative bacilli.",
        "intended use": "The VITEK\u00ae2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK\u00ae2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp., S. pneumoniae and clinically significant yeast.",
        "measurand": "The VITEK 2 AST-Gram Negative card contains the following concentrations of Ceftriaxone: 0.12, 0.25, 1, 4 and 16\u03bcg/mL",
        "panel": "83 Microbiology",
        "predicate 510k number": "K121546",
        "predicate device name": "VITEK\u00ae2 AST-GN Doxycycline",
        "product code": "LON - Fully automated short-term incubation cycle antimicrobial susceptibility system, LTW \u2013 Susceptibility Test Cards, Antimicrobial, LTT \u2013 Panels, Test, Susceptibility, Antimicrobial",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "VITEK\u00ae2 Gram Negative Ceftriaxone (\u2264 0.25 - \u226564 \u00b5g/mL)",
        "purpose for submission": "To obtain a substantial equivalence determination for Ceftriaxone for testing of gram negative bacilli on the VITEK\u00ae2 and VITEK\u00ae2 Compact Antimicrobial Susceptibility Test (AST) Systems.",
        "regulation section": "21 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System",
        "type of test": "Automated quantitative or qualitative antimicrobial susceptibility test for Ceftriaxone"
    },
    "K182353.txt": {
        "510k number": "K182353",
        "applicant": "Phadia AB",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "Same as Intended Uses",
        "intended use": "EliA CENP is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to CENP in human serum and plasma (Li-heparin, EDTA) as an aid in the clinical diagnosis of scleroderma (CREST Syndrome) in conjunction with other laboratory and clinical findings",
        "measurand": "IgG autoantibodies specific to Centromere protein (CENP), U1 ribonucleoprotein (U1RNP), and ribonucleoprotein 70kDa (RNP70)",
        "panel": "Immunology (82)",
        "predicate 510k number": "K082759, K083117",
        "predicate device name": "EliA CENP on Phadia 250, EliA U1RNP on Phadia 250, EliA RNP70 on Phadia 250",
        "product code": "LJM, LKO",
        "proposed labeling": "The labelling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "EliA CENP Immunoassay, EliA U1RNP Immunoassay, El RNP70 Immunoassay",
        "purpose for submission": "Addition of previously cleared assays on a new instrument platform (Phadia 2500/5000)",
        "regulation section": "21 CFR 866.5100",
        "type of test": "Automated semi-quantitative solid-phase fluoroimmunoassays"
    },
    "K162333.txt": {
        "510k number": "K162333",
        "applicant": "Guangzhou Wondfo Biotech Co., Ltd.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "Wondfo One Step Fecal Occult Blood Test is a rapid test for the qualitative detection of human occult blood in feces.  It is used as an aid in the diagnosis of gastrointestinal (GI) bleeding.",
        "measurand": "Human hemoglobin (hHb) in feces",
        "panel": "Hematology (81)",
        "predicate 510k number": "K110309",
        "predicate device name": "FOB One Step Rapid Test (Orient Gene Biotech)",
        "product code": "KHE, Reagent, Occult Blood",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Wondfo One Step Fecal Occult Blood Test",
        "purpose for submission": "Clearance of a new device",
        "regulation section": "21 CFR 864.6550, Occult blood test",
        "type of test": "Lateral flow chromatographic immunoassay"
    },
    "K180607.txt": {
        "510k number": "K180607",
        "applicant": "KRONUS Market Development Associates, INC.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as intended use",
        "intended use": "The KRONUS Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit is for the qualitative determination of antibodies to steroid 21-hydroxylase (21-OH) in human serum.",
        "measurand": "Steroid 21-Hydroxylase Antibody (21-OHAb)",
        "panel": "Immunology (82)",
        "predicate 510k number": "K121046",
        "predicate device name": "KRONUS 21-OHAb RIA Assay Kit",
        "product code": "PCG, 21-Hydroxylase Antibody (21-OHAb) antibody assay",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "KRONUS Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit",
        "purpose for submission": "New device",
        "regulation section": "21 CFR \u00a7 866.5660, Multiple autoantibody immunological test system",
        "type of test": "Manual enzyme-linked immunosorbent assay, qualitative"
    },
    "K173202.txt": {
        "510k number": "K173202",
        "applicant": "Sekisui Medical Co., LTD",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "Same as Intended Use(s) above",
        "intended use": "The CP3000 is a fully automated, random-access in vitro blood coagulation analyzer intended for use by healthcare professionals in the clinical laboratory",
        "measurand": "Antithrombin activity (%)",
        "panel": "Hematology (81)",
        "predicate 510k number": "K160276, K062431, K041905, K021023, K021024",
        "predicate device name": "ACL TOP 700 LAS, HemosIL Liquid Antithrombin, HemosIL Calibration Plasma, HemosIL Normal Control Assayed, HemosIL Low Abnormal Control Assayed",
        "product code": "JPA, JBQ, JIX, GGN",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "CP3000 Coagulation Analyzer, Coagpia AT Reagent, Coagpia Calibrator, Coagpia Control Set",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 864.5425, 21 CFR 864.7060, 21 CFR 862.1150",
        "type of test": "Quantitative chromogenic test"
    },
    "K163260.txt": null,
    "K141689.txt": {
        "510k number": "k141689",
        "applicant": "Qualigen, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "For evaluation of conditions thought to be associated with inflammation, in otherwise healthy individuals.",
        "intended use": "See indication for use.",
        "measurand": "C-reactive protein (CRP)",
        "panel": "Clinical Chemistry",
        "predicate 510k number": "k051564, k050537, k041799",
        "predicate device name": "Olympus CRP Latex Reagent, Bio-Rad Laboratories Liquichek Cardiac Markers Plus Control, Ortho-Clinical Diagnostics, Inc. VITRO Chemistry Products hsCRP Performance Verifier, I, II, and III",
        "product code": "DCK, JIT, JJX",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "FastPack High Sensitivity C-Reactive Protein Immunoassay, FastPack High Sensitivity C-Reactive Protein Calibrator Kit, FastPack High Sensitivity C-Reactive Protein Controls, FastPack High Sensitivity C-Reactive Protein Method Verification Kit",
        "purpose for submission": "New assay",
        "regulation section": "21 CFR 866.5270, 21 CFR 862.1150, 21 CFR 862.1660",
        "type of test": "Quantitative"
    },
    "K182513.txt": null,
    "K161258.txt": null,
    "K161619.txt": {
        "510k number": "K161619",
        "applicant": "Cepheid",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "Same as intended use",
        "intended use": "The Cepheid Xpert TV Assay, performed on the GeneXpert Instrument Systems, is a qualitative in vitro diagnostic test for the detection of Trichomonas vaginalis genomic DNA",
        "measurand": "Trichomonas vaginalis (TV) DNA",
        "panel": "Microbiology (83)",
        "predicate 510k number": "K151565",
        "predicate device name": "Cepheid Xpert TV assay",
        "product code": "OUY- Trichomonas vaginalis nucleic acid amplification test, OOI- Real time nucleic acid amplification system",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "Proprietary Name: Xpert TV, Common names: Xpert TV assay, Xpert Trichomonas Assay",
        "purpose for submission": "The purpose of this submission is to add male urine specimens for use with the Xpert Trichomonas vaginalis (TV) assay",
        "regulation section": "21 CFR 866.3860, Trichomonas vaginalis nucleic acid assay",
        "type of test": "Nucleic acid amplification test using real-time polymerase chain reaction (PCR)"
    },
    "K150526.txt": {
        "510k number": "k150526",
        "applicant": "The Binding Site Group, Ltd.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The Optilite IgG4 kit is intended for the quantitative in vitro measurement of IgG4 in serum using the Binding Site Optilite analyser.",
        "measurand": "IgG4 subclass Antibody",
        "panel": "Immunology (82)",
        "predicate 510k number": "k072889",
        "predicate device name": "Binding Site Human IgG and IgG subclass (IgG1, IgG2, IgG3, IgG4) liquid reagent kits for use on the SPAplus",
        "product code": "CFN - Method, Nephelometric, Immunoglobulins (G, A, M)",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Optilite\u00ae IgG4 Kit",
        "purpose for submission": "New Device",
        "regulation section": "21 CFR \u00a7866.5510 - Immunoglobulins A, G, M, D, E Immunological Test System",
        "type of test": "Quantitative, turbidimetric"
    },
    "K171974.txt": {
        "510k number": "K171974",
        "applicant": "Quidel Corporation",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "As a diagnostic aid in patients with signs and symptoms of respiratory infection.",
        "intended use": "The Solana RSV+hMPV Assay is a qualitative in vitro diagnostic test for the detection and differentiation of RSV and hMPV viral RNA in nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection.",
        "measurand": "RSV RNA: Matrix Gene, hMPV RNA: Fusion Protein Gene",
        "panel": "Microbiology (83)",
        "predicate 510k number": "K131813",
        "predicate device name": "Lyra RSV+hMPV Assay",
        "product code": "Primary: OCC Respiratory Viral Panel Multiplex Nucleic Acid Assay, Secondary: OEM Human Metapneumovirus (hMPV) RNA Assay System",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Solana RSV+hMPV Assay",
        "purpose for submission": "New device; to obtain market clearance for the Solana RSV+hMPV Assay when performed on the Solana instrument.",
        "regulation section": "21 CFR 866.3980 Respiratory viral panel multiplex nucleic acid assay",
        "type of test": "Reverse Transcriptase - Helicase-Dependent Amplification (RT-HDA)"
    },
    "K160585.txt": {
        "510k number": "K160585",
        "applicant": "Streck, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as intended use",
        "intended use": "XN CAL is used for the calibration and calibration verification of Sysmex XN series (XN-10, XN-11, XN-20, XN-21, XN-L) analyzers.",
        "measurand": "Assayed hematology parameters: WBC (103/\u03bcL), RBC (106/\u03bcL), HGB (g/dL), HCT (%), PLT (103/\u03bcL), and RET (%)",
        "panel": "Hematology (81)",
        "predicate 510k number": "K141962",
        "predicate device name": "XN CAL",
        "product code": "KRX",
        "proposed labeling": "The provided labeling is sufficient and satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "XN CAL",
        "purpose for submission": "To expand the intended use of an existing cleared calibrator (XN CAL; K141962) for use on an additional analyzer, the Sysmex XN-L Analyzer.",
        "regulation section": "21 CFR \u00a7 864.8150, Calibrator for cell indices",
        "type of test": "Quantitative"
    },
    "K180209.txt": {
        "510k number": "k180209",
        "applicant": "Diazyme Laboratories Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Diazyme 1,5-anhydroglucitol (1,5-AG) Assay is an enzymatic method intended for the quantitative determination of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The 1,5-AG Assay is for the intermediate term (preceding 1-2 weeks) monitoring of glycemic control in people with diabetes. For in vitro diagnostic use only.",
        "intended use": "See indications for use below.",
        "measurand": "1,5-Anhydroglucitol (1,5-AG)",
        "panel": "Hematology (81)",
        "predicate 510k number": "k031604",
        "predicate device name": "GlycoMark",
        "product code": "NOZ; Assay, 1,5-Anhydroglucitol",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.",
        "proprietary and established names": "Diazyme 1,5-AG Assay",
        "purpose for submission": "New Device",
        "regulation section": "21 CFR 864.7470; Glycosylated hemoglobin assay",
        "type of test": "Quantitative, colorometric, pyranose oxidase (PROD)"
    },
    "K143502.txt": {
        "510k number": "k143502",
        "applicant": "Immunalysis Corporation",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "The Immunalysis Opiates Urine Enzyme Immunoassay is a homogeneous enzyme immunoassay with a dual cutoff of 300ng/mL and 2000ng/mL",
        "intended use": "For the qualitative and semi-quantitative analysis of opiates in human urine with automated clinical chemistry analyzers",
        "measurand": "Opiates",
        "panel": "91 \u2013 Toxicology",
        "predicate 510k number": "k011150, k051088",
        "predicate device name": "DRI DAU Opiate Assay, LZI Multiple Analyte Urine Drugs of Abuse Calibrators and Controls",
        "product code": "DJG, DLJ, DIF",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "Immunalysis Opiates Enzyme Immunoassay, Immunalysis Opiates Urine Calibrators 300, Immunalysis Opiates Urine Calibrators 2000, Immunalysis Multi-Drug Controls",
        "purpose for submission": "New device",
        "regulation section": "862.3650, 862.3200, 862.3280",
        "type of test": "Qualitative and semi-quantitative homogeneous enzyme immunoassay"
    },
    "K163626.txt": null,
    "K173505.txt": {
        "510k number": "K173505",
        "applicant": "ForaCare Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The FORA GTel Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertip. It is intended for in vitro diagnostic use by people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program.",
        "intended use": "The FORA GTel Blood Glucose Monitoring System consists of the FORA GTel Test Strip and the FORA GTel Blood Glucose meter. The FORA GTel Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertip.",
        "measurand": "Capillary whole blood glucose from the fingertip",
        "panel": "Clinical Chemistry (75)",
        "predicate 510k number": "k143467",
        "predicate device name": "FORA GD43 Blood Glucose Monitoring System",
        "product code": "NBW, System Test, Blood Glucose, Over the Counter",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "FORA GTel Blood Glucose Monitoring System",
        "purpose for submission": "New Device",
        "regulation section": "21 CFR 862.1345, Glucose test system",
        "type of test": "Quantitative amperometric assay (Glucose Dehydrogenase FAD)"
    },
    "K182357.txt": {
        "510k number": "K182357",
        "applicant": "Hardy Diagnostics",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Use of HardyDisk AST Eravacycline 20\u00b5g (ERV20) for in vitro agar diffusion susceptibility testing is indicated when there is need to determine the susceptibility of bacteria among the Enterobacteriaceae to Eravacyline.",
        "intended use": "HardyDisk AST Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens.",
        "measurand": "Eravacycline 20\u00b5g",
        "panel": "83, Microbiology",
        "predicate 510k number": "K062245",
        "predicate device name": "HardyDisk Tigecycline 15\u00b5g",
        "product code": "JTN",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device.",
        "proprietary and established names": "HardyDisk AST Eravacycline 20\u00b5g (ERV20)",
        "purpose for submission": "To obtain a substantial equivalence determination for Eravacycline Antimicrobial Susceptibility Test Disk",
        "regulation section": "21 CFR 866.1620 Antimicrobial Susceptibility Test Disc",
        "type of test": "Antimicrobial Susceptibility Test Disks"
    },
    "K143075.txt": {
        "510k number": "k143075",
        "applicant": "Tosoh Bioscience",
        "classification": "Class I, reserved",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The ST AIA-PACK SHBG is designed for In Vitro Diagnostic Use Only for the quantitative measurement of sex hormone binding globulin (SHBG) in human serum or Na heparinized plasma on Tosoh AIA System Analyzers. The ST AIA-PACK SHBG assay is intended for use as an aid in the diagnosis of androgen disorders.",
        "intended use": "For the quantitative measurement of sex hormone binding globulin (SHBG) in human serum and plasma for use as an aid in the diagnosis of androgen disorders.",
        "measurand": "Sex Hormone Binding Globulin (SHBG)",
        "panel": "Clinical Chemistry (75)",
        "predicate 510k number": "k060818",
        "predicate device name": "Architect SHBG Reagent Kit",
        "product code": "CDZ",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "ST AIA-PACK SHBG, ST AIA-PACK SHBG Calibrator Set",
        "purpose for submission": "New Device",
        "regulation section": "21 CFR 862.1680",
        "type of test": "Quantitative immunoassay"
    },
    "K150815.txt": {
        "510k number": "K150815",
        "applicant": "BD Biosciences",
        "classification": "Class II (assay) Class II (controls)",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "Normal and HIV positive patients in conjunction with other laboratory and clinical findings",
        "intended use": "For use with the BD FACSPresto CD4/Hb Cartridge and BD FACSPresto CD4/Hb Cartridge Kit in the direct quantification and enumeration of CD4 absolute count, CD4 of lymphocyte, and determination of hemoglobin concentration",
        "measurand": "Lymphocyte CD4 absolute count, CD4 percentage of lymphocytes, and hemoglobin concentration",
        "panel": "Hematology (81) Immunology (82)",
        "predicate 510k number": "K071141 K981761 K961610 BK990005 K982231 BK030067",
        "predicate device name": "BD FACSCalibur using BD Tritest CD3/CD4/CD45 with BD Trucount Tubes Sysmex Automated Hematology Analyzer KX-21N R&D Systems Whole Blood Flow Control (StatusFlow- K961610 & BK990005) Eurotrol Hb 301 Control (Levels 1\u22123)",
        "product code": "PMG OYE GKL JPK",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "BD FACSPresto System BD FACSPresto CD4/Hb Cartridge BD FACSPresto CD4/Hb Cartridge Kit BD Multi-Check Control BD Multi-Check CD4 Low Control Eurotrol FACSPresto Hb Control",
        "purpose for submission": "New assay and instrument",
        "regulation section": "21 CFR \u00a7864.5220 21 CFR \u00a7864.8625",
        "type of test": "Quantitative test for CD4% and CD4 absolute count by cytometry imaging and quantitative test for hemoglobin by absorbance spectrometer"
    },
    "K152386.txt": {
        "attribute1": "K152386",
        "attribute2": "Luminex Molecular Diagnostics, Inc.",
        "attribute3": "Class II",
        "attribute4": "Substantially equivalent to predicate device",
        "attribute5": "qualitative Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay for the in vitro qualitative detection of multiple respiratory viruses and bacteria",
        "attribute6": "NxTAG Respiratory Pathogen Panel",
        "attribute7": "NxTAG Respiratory Pathogen Panel",
        "attribute8": "21 CFR 866.3980",
        "attribute9": "Influenza A, Influenza A H1, Influenza A H3, Influenza B, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Coronavirus 229E, Coronavirus OC43, Coronavirus NL63, Coronavirus HKU1, Human Metapneumovirus, Rhinovirus/Enterovirus, Adenovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Human Bocavirus, Chlamydophila pneumoniae, and Mycoplasma pneumoniae",
        "attribute10": "K120267",
        "attribute11": "BioFire Diagnostics, LLC FilmArray Respiratory Panel",
        "attribute12": "OCC",
        "attribute13": "Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR)"
    },
    "K170293.txt": {
        "510k number": "k170293",
        "applicant": "Siemens Healthcare Diagnostics, Inc.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Emit II Plus Cocaine Metabolite Assay is a homogeneous enzyme immunoassay with a 150 ng/mL or 300 ng/mL cutoff. The assay is intended for use in the qualitative and semiquantitative analyses of benzoylecgonine (cocaine metabolite) in human urine.",
        "intended use": "For Prescription use only. The Emit II Plus Cocaine Metabolite Assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result.",
        "measurand": "Benzoylecgonine",
        "panel": "91 - Toxicology",
        "predicate 510k number": "k993988",
        "predicate device name": "Emit II Plus Cocaine Metabolite Assay",
        "product code": "DIO",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Emit II Plus Cocaine Metabolite Assay",
        "purpose for submission": "Adding a previously cleared test (Emit II Plus Cocaine Metabolite Assay) to the Beckman Coulter DxC 700 AU Clinical Chemistry Analyzer",
        "regulation section": "21 CFR 862.3250",
        "type of test": "Qualitative and semi-quantative homogenous enzyme immunoassay"
    },
    "K182922.txt": {
        "510k number": "K182922",
        "applicant": "Liofilchem s.r.l.",
        "classification": "II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "Same as Intended Use",
        "intended use": "The Liofilchem MTS (MIC Test Strip) Omadacycline 0.002-32 \u03bcg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "measurand": "Omadacycline 0.002-32 \u03bcg/mL",
        "panel": "83 \u2013 Microbiology",
        "predicate 510k number": "K153687",
        "predicate device name": "Liofilchem MTS, vancomycin",
        "product code": "JWY - Manual Antimicrobial Susceptibility Test Systems",
        "proposed labeling": "The labeling supports the finding of substantial equivalence for this device.",
        "proprietary and established names": "MTS Omadacycline 0.002-32 \u03bcg/mL",
        "purpose for submission": "To obtain a substantial equivalence determination for Omadacycline (OMC) at concentrations of 0.002-32 \u00b5g/mL for susceptibility testing of non-fastidious Gram-negative and non-fastidious Gram-positive organisms",
        "regulation section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "type of test": "Quantitative Antimicrobial Susceptibility Test growth-based detection"
    },
    "K150281.txt": {
        "510k number": "k150281",
        "applicant": "Nova Biomedical Corporation",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The StatStrip Glucose Hospital Meter System is intended for point-of-care, in vitro diagnostic, multiple-patient use for the quantitative determination of glucose in capillary finger stick, venous whole blood, arterial whole blood, neonate arterial whole blood and neonate heel stick specimens.",
        "intended use": "The StatStrip Glucose Hospital Meter System is intended for point-of-care, in vitro diagnostic, multiple-patient use for the quantitative determination of glucose in capillary finger stick, venous whole blood, arterial whole blood, neonate arterial whole blood and neonate heel stick specimens.",
        "measurand": "Capillary whole blood glucose, venous, arterial, neonate arterial, and neonate heelstick samples.",
        "panel": "Clinical Chemistry (75)",
        "predicate 510k number": "K132121",
        "predicate device name": "Nova StatStrip Glucose Hospital Meter System",
        "product code": "CGA, Glucose Oxidase, Glucose",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "StatStrip Glucose Hospital Meter System",
        "purpose for submission": "Modified device to add wireless (Wi-Fi) connectivity, modify the meter layout and revise the accompanying docking/charging station.",
        "regulation section": "21 CFR 862.1345, Glucose test system",
        "type of test": "Quantitative amperometric assay, glucose oxidase"
    },
    "K161831.txt": {
        "510k number": "k161831",
        "applicant": "Immunodiagnostic Systems Limited",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The IDS-iSYS 25 VitDS  Assay is intended for the quantitative determination  of  total   25-hydroxyvitamin  D  [(25(OH)D]  in human  serum  or  plasma  on  the  IDS-iSYS   Multi-Discipline Automated System. Results are to be used in conjunction with other  clinical and laboratory data to assist the clinician in the assessment of vitamin D  sufficiency in an adult population.",
        "intended use": "See indications for use below.",
        "measurand": "Total 25-hydroxyvitamin D",
        "panel": "Clinical Chemistry (75)",
        "predicate 510k number": "k140554",
        "predicate device name": "IDS-iSYS 25-Hydroxy Vitamin DS Assay",
        "product code": "MRG, Vitamin D Test System, JJX, Single (specified) Analyte Controls (Assayed and Unassayed)",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "IDS-iSYS 25VitDS, IDS-iSYS 25VitDS Control Set",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 862.1825, Vitamin D Test System, 21 CFR 862.1660, Quality Control Material",
        "type of test": "Quantitative chemiluminescent immunoassay"
    },
    "K172287.txt": {
        "510k number": "K172287",
        "applicant": "QIAGEN",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The test is intended for use as an adjunct to evaluation of suspected myeloproliferative neoplasms, in conjunction with other clinicopathological factors.",
        "intended use": "The ipsogen JAK2 RGQ PCR Kit is a qualitative in vitro diagnostic test for the detection of the JAK2 V617F/G1849T allele in genomic DNA extracted from EDTA whole blood.",
        "measurand": "Janus Tyrosine Kinase 2 (JAK2) gene mutation G1849T (V617F)",
        "panel": "88 \u2013 Pathology",
        "predicate 510k number": "DEN160028",
        "predicate device name": "ipsogen JAK2 RGQ PCR Kit",
        "product code": "PSU",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809 and the special controls for this device type.",
        "proprietary and established names": "QIAGEN ipsogen JAK2 RGQ PCR Kit",
        "purpose for submission": "Expansion of the Indications for Use.",
        "regulation section": "21 CFR 866.6070",
        "type of test": "Allele-specific, quantitative, polymerase chain reaction (PCR) using an amplification refractory mutation system (ARMS)"
    },
    "K170974.txt": {
        "510k number": "K170974",
        "applicant": "BD Biosciences",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "immunophenotyping using up to six fluorescence detection channels and two light scatter channels",
        "intended use": "The BD FACSLyric flow cytometer is intended for use as an in vitro diagnostic device for immunophenotyping",
        "measurand": "percentages and absolute counts of the following mature human lymphocyte subsets",
        "panel": "Hematology (81)",
        "predicate 510k number": "K141468; K062087; K980858; K974360; K090967; K040026; K961610; K982231; K970836",
        "predicate device name": "BD FACSCanto II",
        "product code": "OYE",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "BD FACSLyric Flow Cytometer",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 864.5220",
        "type of test": "Quantitative and Semi-quantitative Flow Cytometric Immunoassays"
    },
    "K151917.txt": {
        "510k number": "k151917",
        "applicant": "Luminex Corporation",
        "classification": "Class II (special controls)",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "indications for use": "The Luminex ARIES System is an in vitro diagnostic (IVD) platform that performs nucleic acid based tests in clinical laboratories",
        "intended use": "For prescription use only",
        "measurand": "Nucleic acid",
        "panel": "Chemistry (75)",
        "predicate 510k number": "k111860",
        "predicate device name": "BD MAX System",
        "product code": "OOI",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10",
        "proprietary and established names": "ARIES System",
        "purpose for submission": "New instrument for use with the ARIES HSV 1&2 Assay cleared under k151906",
        "regulation section": "21 CFR 862.2570",
        "type of test": "Nucleic-acid amplification testing"
    },
    "K162526.txt": {
        "510k number": "k162526",
        "applicant": "Roche Diagnostics",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The Creatine Kinase-MB assay is an in vitro test for the quantitative determination of the catalytic activity of creatine kinase MB subunit (CK-MB) in human serum and plasma on Roche/Hitachi cobas c systems.",
        "intended use": "In vitro quantitative determination of the catalytic activity of creatine kinase MB subunit (CK-MB) in human serum and plasma.",
        "measurand": "Creatine kinase MB subunit",
        "panel": "Clinical Chemistry (75)",
        "predicate 510k number": "k003158",
        "predicate device name": "Roche CK-MB",
        "product code": "JHW, U.V. Method, Cpk Isoenzymes",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "Creatine Kinase-MB",
        "purpose for submission": "New device",
        "regulation section": "21 CFR 862.1215, Creatine phosphokinase/creatine kinase or isoenzymes test system",
        "type of test": "Quantitative, enzymatic assay"
    },
    "K193393.txt": {
        "510k number": "K193393",
        "applicant": "Leica Biosystems Newcastle Ltd.",
        "classification": "Class II",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "indications for use": "The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient\u2019s clinical history and other diagnostic tests by a qualified pathologist. Progesterone Receptor Clone (16) is indicated as an aid in the management, prognosis and prediction of therapy outcome of breast cancer.",
        "intended use": "For in vitro diagnostic use.",
        "measurand": "Human Progesterone Receptor in formalin-fixed, paraffin embedded breast cancer tissue.",
        "panel": "Immunohistochemistry Reagents and Kits",
        "predicate 510k number": "K171753",
        "predicate device name": "BOND Ready-to-Use Primary Antibody Progesterone Receptor (16), Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone 16",
        "product code": "MXZ",
        "proposed labeling": "The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.",
        "proprietary and established names": "BOND Ready-to-Use Primary Antibody Progesterone Receptor (16), Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone 16 (Concentrated Liquid Antibody Format)",
        "purpose for submission": "Leica Biosystems Newcastle Ltd., is submitting this traditional 510(k) notification to request modifications to their BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16) and Concentrated Liquid Mouse Monoclonal Antibody (Novocastra), previously cleared under K062615, K171753 and K183102 for the BOND-MAX instrument.",
        "regulation section": "21 CFR 864.1860",
        "type of test": "Immunohistochemistry (IHC)"
    }
}